CoChat

CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer

Open access
Iyengar, Mangala, O’Hayer, Patrick, Cole, Alex, Sebastian, Tara, Yang, Kun, Coffman, Lan, Buckanovich, Ronald J. · 2018 · Oncotarget
Cited by 75

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

// Mangala Iyengar 1, 2, * , Patrick O’Hayer 1, 2, * , Alex Cole 4 , Tara Sebastian 3 , Kun Yang 4 , Lan Coffman 4, # and Ronald J. Buckanovich 4, 5, # 1 University of Michigan, Department of Cellular and Molecular Biology, Ann Arbor, MI 48109, USA 2 University of Michigan, Medical Scientist Training Program, Ann Arbor, MI 48109, USA 3 University of Michigan, School of Literature, Science and the Arts, Ann Arbor, MI 48109, USA 4 University of Michigan, Division of Hematology and Oncology, Department of Internal Medicine, Ann Arbor, MI 48109, USA 5 Magee Women’s Research Institute, University of Pittsburgh, Department of Internal Medicine, Pittsburgh, PA 15213, USA * Co-first authors # Co-senior authors Correspondence to: Ronald J. Buckanovich, email: ronaldbu@med.umich.edu Keywords: ovarian cancer; Ribociclib; CDK 4/6 inhibitor; chemotherapy resistance; cell cycle Abbreviations: LEE-011: Ribociclib; CDK: Cyclin Dependent Kinase; HGSOC: high grade serous ovarian cancer; TCGA: The Cancer Genome Atlas Received: February 20, 2018 Accepted: February 21, 2018 Epub: February 26, 2018 Published: March 20, 2018 ABSTRACT High grade serous ovarian cancer (HGSOC) is a disease with a high relapse rate and poor overall survival despite good initial responses to platinum-based therapy. Cell cycle inhibition with targeted CDK4/6 inhibitors is a new therapeutic approach showing promise as a maintenance therapy in cancer. As multiple genes in the CDK4/6 pathway are commonly mutated or dysregulated in ovarian cancer, we evaluated the efficacy of the CDK4/6 inhibitor Ribociclib alone, in combination with chemotherapy, and as maintenance therapy in several models of HGSOC. Ribociclib restricted cellular proliferation in multiple ovarian cancer cell lines. Restricted proliferation was associated with a pseudo-senescent cellular phenotype; Ribociclib-treated cells expressed markers of senescence, but could rapidly re-enter the cell cycle with discontinuation of therapy. Surprisingly, concurrent Ribociclib and cisplatin therapy followed by Ribociclib maintenance was synergistic. Evaluation of the cell cycle suggested that Ribociclib may also act at the G2/M check point via dephosphorylation of ATR and CHK1. Consistent with this mechanism, Ribociclib demonstrated clear activity in both platinum-resistant and platinum-sensitive tumor models in vivo . This work supports clinical trials using Ribociclib in combination with cisplatin and as a maintenance therapy in ovarian cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.24585

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

Metadata

Authors
Iyengar, M., O’Hayer, P., Cole, A., Sebastian, T., Yang, K., Coffman, L., & Buckanovich, R. J.
Venue
Oncotarget
Published
2018-02-26
Volume
9
Issue
21
Pages
15658-15672
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2790864476
Cited by
75
References
12
FWCI
10.10
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.